Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
University of Florida
University of Arizona
Janssen Research & Development, LLC
UNC Lineberger Comprehensive Cancer Center
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
First Affiliated Hospital of Wenzhou Medical University
Assiut University
National Cancer Center, Korea
M.D. Anderson Cancer Center
G1 Therapeutics, Inc.
Columbia University
Merck Sharp & Dohme LLC
Hospital Centre Biel/Bienne
Institut du Cancer de Montpellier - Val d'Aurelle
A.O.U. Città della Salute e della Scienza
SWOG Cancer Research Network
Zhujiang Hospital
SWOG Cancer Research Network
Fudan University
Hoosier Cancer Research Network
The University of Texas Health Science Center at San Antonio
University of Bern
SCRI Development Innovations, LLC
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Radiation Therapy Oncology Group
Masonic Cancer Center, University of Minnesota
University Health Network, Toronto
M.D. Anderson Cancer Center
Karolinska University Hospital
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
Cardiff University
The University of Texas Health Science Center, Houston
Cardiff University
Wake Forest University Health Sciences
Medical University of South Carolina
Radiation Therapy Oncology Group
Yale University
Memorial Sloan Kettering Cancer Center
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Brown University
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center